Hikma has secured an extension to file its brief in opposition to Amarin’s petition to the US Supreme Court for certiorari review of a US Court of Appeals for the Federal Circuit decision that opened the door for the launch of the first generic version of the originator’s Vascepa (icosapent ethyl) purified fish oil brand.
The newly-allotted time is less than half of the 45-day extension initially requested by the generics player, after Amarin argued...






